Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 100870

1.

Identification of the C-Reactive Protein Interaction Network Using a Bioinformatics Approach Provides Insights into the Molecular Pathogenesis of Hepatocellular Carcinoma.

She S, Jiang L, Zhang Z, Yang M, Hu H, Hu P, Liao Y, Yang Y, Ren H.

Cell Physiol Biochem. 2018 Jul 19;48(2):741-752. doi: 10.1159/000491903. [Epub ahead of print]

2.

Preoperative albumin-bilirubin grade plus platelet-to-lymphocyte ratio predict the outcomes of patients with BCLC stage A hepatocellular carcinoma after liver resection.

Li C, Zhang XY, Peng W, Wen TF, Yan LN, Li B, Yang JY, Wang WT, Xu MQ, Chen LP.

Medicine (Baltimore). 2018 Jul;97(29):e11599. doi: 10.1097/MD.0000000000011599.

3.

Impact of immigration in presentation and outcomes of hepatocellular carcinoma in the USA.

Ashhab AA, Rodin H, Powell J, Debes JD.

Eur J Gastroenterol Hepatol. 2018 Jul 18. doi: 10.1097/MEG.0000000000001212. [Epub ahead of print]

PMID:
30024491
4.

In Vitro Carcinoma Treatment Using Magnetic Nanocarriers under Ultrasound and Magnetic Fields.

Sengupta S, Khatua C, Balla VK.

ACS Omega. 2018 May 31;3(5):5459-5469. doi: 10.1021/acsomega.8b00105. Epub 2018 May 21.

PMID:
30023921
5.

Sorafenib-Induced Acute Pancreatitis in a Patient with Differentiated Thyroid Cancer.

Kattah Martinez LX, Marín Carrillo LF, Rojas Melo L.

Eur Thyroid J. 2018 Jun;7(3):145-148. doi: 10.1159/000488316. Epub 2018 Apr 25.

PMID:
30023347
6.

Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma.

Chen H, Zhang Y, Li S, Li N, Chen Y, Zhang B, Qu C, Ding H, Huang J, Dai M.

Cancer Manag Res. 2018 Jul 10;10:1947-1958. doi: 10.2147/CMAR.S167036. eCollection 2018.

7.

IL-1α correlates with severity of hepatitis C virus-related liver diseases.

Tawfik AK, Amin AM, Yousef M, El-Sayd NM, Elashry H, Elkadeem M, Abd-Elsalam S.

J Inflamm Res. 2018 Jul 10;11:289-295. doi: 10.2147/JIR.S166564. eCollection 2018.

8.

The long non-coding RNA n339260 promotes vasculogenic mimicry and cancer stem cell development in hepatocellular carcinoma.

Zhao X, Sun B, Liu T, Shao B, Sun R, Zhu D, Zhang Y, Gu Q, Dong X, Liu F, Zhao N, Zhang D, Li Y, Meng J, Gong W, Zheng Y, Zheng X.

Cancer Sci. 2018 Jul 19. doi: 10.1111/cas.13740. [Epub ahead of print]

9.

Platelet-Albumin Score as a Sensitive Measure for Surgical Risk Prediction and Survival Outcomes of Patients with Hepatocellular Carcinoma.

Shindoh J, Kawamura Y, Kobayashi Y, Kiya Y, Sugawara T, Akuta N, Kobayashi M, Suzuki Y, Ikeda K, Hashimoto M.

J Gastrointest Surg. 2018 Jul 18. doi: 10.1007/s11605-018-3871-1. [Epub ahead of print]

PMID:
30022441
10.

Crosstalk between hepatic tumor cells and macrophages via Wnt/β-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors.

Yang Y, Ye YC, Chen Y, Zhao JL, Gao CC, Han H, Liu WC, Qin HY.

Cell Death Dis. 2018 Jul 18;9(8):793. doi: 10.1038/s41419-018-0818-0.

PMID:
30022048
11.

Hepatitis B virus deregulates cell cycle to promote viral replication and a premalignant phenotype.

Xia Y, Cheng X, Li Y, Valdez K, Chen W, Liang TJ.

J Virol. 2018 Jul 18. pii: JVI.00722-18. doi: 10.1128/JVI.00722-18. [Epub ahead of print]

PMID:
30021897
12.

Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study.

Tapper EB, Parikh ND.

BMJ. 2018 Jul 18;362:k2817. doi: 10.1136/bmj.k2817.

13.

Factors influencing on health-related quality of life in South Korean with chronic liver disease.

Kim HJ, Chu H, Lee S.

Health Qual Life Outcomes. 2018 Jul 18;16(1):142. doi: 10.1186/s12955-018-0964-1.

14.

Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

Ye R, Dai N, He Q, Guo P, Xiang Y, Zhang Q, Hong Z, Zhang Q.

Biomed Pharmacother. 2018 Sep;105:962-973. doi: 10.1016/j.biopha.2018.06.065. Epub 2018 Jun 19.

PMID:
30021391
15.

microRNA-19a-3p promotes tumor metastasis and chemoresistance through the PTEN/Akt pathway in hepatocellular carcinoma.

Jiang XM, Yu XN, Liu TT, Zhu HR, Shi X, Bilegsaikhan E, Guo HY, Song GQ, Weng SQ, Huang XX, Dong L, Janssen HLA, Shen XZ, Zhu JM.

Biomed Pharmacother. 2018 Sep;105:1147-1154. doi: 10.1016/j.biopha.2018.06.097. Epub 2018 Jun 21.

PMID:
30021351
16.

LncRNA NEAT1 Promotes Deterioration of Hepatocellular Carcinoma Based on In Vitro Experiments, Data Mining, and RT-qPCR Analysis.

Ling ZA, Xiong DD, Meng RM, Cen JM, Zhao N, Chen G, Li RL, Dang YW.

Cell Physiol Biochem. 2018 Jul 18;48(2):540-555. doi: 10.1159/000491811. [Epub ahead of print]

17.

Ultrasound for HCC Surveillance: Still Looking for the Fortune Teller.

Foerster F, Galle PR.

Liver Transpl. 2018 Jul 18. doi: 10.1002/lt.25309. [Epub ahead of print]

PMID:
30021053
18.
19.

Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma.

Kotha S, Neong S, Patel K.

Expert Rev Mol Diagn. 2018 Jul 18:1-10. doi: 10.1080/14737159.2018.1496020. [Epub ahead of print]

PMID:
30019978
20.

Nogo-B promotes tumor angiogenesis and provides a potential therapeutic target in hepatocellular carcinoma.

Cai H, Saiyin H, Liu X, Han D, Ji G, Qin B, Zuo J, Shen S, Yu W, Wu J, Wu Y, Yu L.

Mol Oncol. 2018 Jul 18. doi: 10.1002/1878-0261.12358. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center